Bridgeway Capital Management’s Candel Therapeutics CADL Stock Holding History

Bridgeway Capital Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$368K	Buy	75,100 +20,000	+36%	+$109K	0.01%	886
2025 Q4	$311K	Hold	55,100	–	–	0.01%	924
2025 Q3	$281K	Hold	55,100	–	–	0.01%	944
2025 Q2	$279K	Buy	+55,100	New	+$284K	0.01%	882
2025 Q1	–	Sell	-77,195	Closed	-$670K	–	1185
2024 Q4	$670K	Sell	77,195 -3,400	-4%	-$20.1K	0.02%	756
2024 Q3	$559K	Hold	80,595	–	–	0.01%	839
2024 Q2	$500K	Sell	80,595 -2,000	-2%	-$15K	0.01%	860
2024 Q1	$131K	Sell	82,595 -50,000	-38%	-$74.2K	﹤0.01%	1178
2023 Q4	$195K	Hold	132,595	–	–	﹤0.01%	1139
2023 Q3	$123K	Hold	132,595	–	–	﹤0.01%	1188
2023 Q2	$167K	Sell	132,595 -105	-0.1%	-$155	﹤0.01%	1175
2023 Q1	$182K	Hold	132,700	–	–	﹤0.01%	1121
2022 Q4	$238K	Hold	132,700	–	–	0.01%	1046
2022 Q3	$417K	Hold	132,700	–	–	0.01%	939
2022 Q2	$430K	Buy	132,700 +57,700	+77%	+$231K	0.01%	913
2022 Q1	$382K	Buy	+75,000	New	+$372K	0.01%	1010

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's CADL Position: Q1 2026 in Review

Bridgeway Capital Management increased its Candel Therapeutics (CADL) stake by 36% in Q1 2026, buying an estimated $109K and bringing the position to 75,100 shares worth $368K. The position accounts for 0.01% of the portfolio, ranked #886.

Bridgeway Capital Management first reported a position in CADL in Q1 2022 and has held it in 16 quarters since. The position peaked at $670K in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Bridgeway Capital Management held 75,100 shares of Candel Therapeutics worth $368K as of Q1 2026.
Bridgeway Capital Management bought 20,000 Candel Therapeutics shares in Q1 2026, an estimated $109K.
Candel Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #886 holding.
Bridgeway Capital Management first reported a position in Candel Therapeutics in Q1 2022 and has held it in 16 quarters since.
Bridgeway Capital Management's Candel Therapeutics position peaked at $670K in Q4 2024.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.